Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

Scilex Receives Fast Track Designation for Back Pain Combo Product
Scilex Receives Fast Track Designation for Back Pain Combo Product

Scilex, a Sorrento Therapeutics subsidiary, has received Fast Track designation from the FDA for its investigational drug and device product candidate SP-103.

Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity
Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity
Dr. Reddy's Laboratories, Inc. (today announced the launch, in the U.S. market, of Lenalidomide Capsules, a therapeutic equivalent generic version of REVLIMID® (lenalidomide) Capsules approved by ...
Valneva and VBI Vaccines Ink Partnership Deal Over Hepatitis B Vaccine
Valneva and VBI Vaccines Ink Partnership Deal Over Hepatitis B Vaccine

Valneva and VBI Vaccines have entered a partnership deal over VBI Vaccines’ hepatitis B vaccine PreHevbri.

Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
Revance Therapeutics, Inc., (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administra...
EC Approves Kite’s Tecartus for Relapsed/Refractory Acute Lymphoblastic Leukemia
EC Approves Kite’s Tecartus for Relapsed/Refractory Acute Lymphoblastic Leukemia
The European Commission (EC) has granted marketing authorization for Gilead subsidiary Kite’s Tecartus (brexucabtagene autoleucel) for the treatment of adult patients 26 years and older who have ...
AmMax Bio Announces AMB-05X Granted FDA Fast Track Designation for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
AmMax Bio Announces AMB-05X Granted FDA Fast Track Designation for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, including targeting the colony-stimulating factor 1 receptor (CSF1R...
8 billions: CVS to Buy Signify Health in Deal Pushing Beyond Retail
8 billions: CVS to Buy Signify Health in Deal Pushing Beyond Retail

CVS Health Corp. emerged as the winning bidder over potential suitors that had included UnitedHealth Group Inc., Amazon.com Inc. and Option Care Health Inc.

FDA Expands Approval of Vertex’s Orkambi to Include Younger Age Group
FDA Expands Approval of Vertex’s Orkambi to Include Younger Age Group
The FDA has expanded its approval of Vertex Pharmaceuticals’ Orkambi (lumacaftor/ivacaftor) to include children with cystic fibrosis (CF) between the ages of 12 and 24 months who are homozygous f...
AstraZeneca’s Imfinzi Gets Expanded FDA Approval for Advanced Biliary Tract Cancer
AstraZeneca’s Imfinzi Gets Expanded FDA Approval for Advanced Biliary Tract Cancer
The FDA has granted expanded approval for AstraZeneca’s blockbuster drug Imfinzi (durvalumab) in combination with chemotherapy gemcitabine and cisplatin to treat adults with locally advanced or ...
Experimental drug combo inhibits growth of lethal lung cancer in mice
Experimental drug combo inhibits growth of lethal lung cancer in mice
Small cell lung cancer (SCLC) is one of the deadliest forms of the disease, but now scientists may have a promising new avenue for treatment. 
Amneal Submits NDA for IPX203 for Parkinson’s Disease
Amneal Submits NDA for IPX203 for Parkinson’s Disease
Amneal Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for its investigational candidate IPX203 for the treatment of patients with Parkinson’s disease. ...
FDA grants Orphan Drug status to Maze’s Pompe disease treatment
FDA grants Orphan Drug status to Maze’s Pompe disease treatment

MZE001 is being assessed in a Phase I trial to evaluate the tolerability, safety, pharmacokinetics and pharmacodynamics.

Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand